The clinical samples also confirmed that the levels of immune microenvironment markers (CD1α and CD4) and ferroptosis markers (CHMP5 and DDIT3) were lower in high-grade ovarian cancer tissues. This evidence concerns the gene CD1A and ovarian carcinoma.